Melanotan I
Melanotan I
Also known as: Afamelanotide, MT-1, CUV1647, Scenesse
Overview
Key Facts
Primary Goal: Research and therapeutic applications of Melanotan I
Selectively binds melanocortin-1 receptor (MC1R) on melanocytes. Activates cAMP/PKA pathway to upregulate tyrosinase and melanin production.
Dosing Information
~30 minutes to 1 hour
0.5–1 mg
Once daily for 7-10 days, then maintenance every 2-3 days
10-14 day loading phase, then as needed
Benefits
- Induces eumelanin production for UV-free tanning
- Provides photoprotection against UV-induced DNA damage
- Reduces severity of phototoxic reactions in EPP patients
- More selective MC1R activation compared to Melanotan II
- No significant sexual side effects
Side Effects
Mechanism of Action
Selectively binds melanocortin-1 receptor (MC1R) on melanocytes
Activates cAMP/PKA pathway to upregulate tyrosinase and melanin production
Promotes eumelanin (brown/black pigment) over pheomelanin (red/yellow)
Enhances DNA repair mechanisms in UV-exposed keratinocytes
Contraindications
Do not use this peptide if any of the following apply:
- History of melanoma or atypical mole syndrome
- Severe hepatic impairment
- Pregnancy or breastfeeding
- Children under 18
Storage & Reconstitution
Unreconstituted (Powder)
Reconstituted (Mixed)
Note: Protect from light. Do not freeze reconstituted solution.
Research Summary
Developed at the University of Arizona and later by Clinuvel Pharmaceuticals, afamelanotide was approved by the EMA in 2014 and the FDA in 2019 (as Scenesse) for EPP. Phase III trials demonstrated significant increases in pain-free time outdoors and melanin density. Unlike Melanotan II, it shows high MC1R selectivity with minimal off-target effects. Research continues into its potential for vitiligo, polymorphous light eruption, and skin cancer prevention.
Frequently Asked Questions
Common questions about Melanotan I
UK-Specific Information
Exclusive data points and guidance for UK residents using Melanotan I
UK Lab Testing
UK Lab Testing
Recommended labs: Medichecks, Thriva (£89-£149 for peptide safety panel)
Why this matters: UK-specific lab testing guidance not available on US competitor sites
Commonly Stacked With
5-Amino-1MQ
Research and therapeutic applications of 5-Amino-1MQ
Ac-SDKP
Research and therapeutic applications of Ac-SDKP
ACE-031
Research and therapeutic applications of ACE-031
Acetyl Hexapeptide-3
Research and therapeutic applications of Acetyl Hexapeptide-3
AHK-Cu
Research and therapeutic applications of AHK-Cu
Alcohol Prep Pads
Research and therapeutic applications of Alcohol Prep Pads
Note: Peptide stacking should only be done under the guidance of a qualified healthcare professional. Individual responses may vary.
Share on TikTok
Generate a trackable link to share this peptide information on TikTok